CAHHealthcare · Medical DistributionThe 17 Wall Street analysts covering Cardinal Health, Inc. hold a median 12-month price target of $276 — +8.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 15 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Cardinal Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (98): The shares have been drifting up relative to others.
Issuance (69): The company has been issuing shares or taking on financing, diluting existing holders.
Size (4): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CAH, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +8.6% from it.
Of the 20 most recent actions, 15 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 Aug 2026 | RBC Capital | Initiates | Outperform | $276 |
| 13 Aug 2026 | Barclays | Maintains | Overweight | $258 → $275 |
| 13 Aug 2026 | JP Morgan | Maintains | Neutral | $215 → $260 |
| 13 Aug 2026 | TD Cowen | Maintains | Buy | $275 → $280 |
| 12 Aug 2026 | Baird | Maintains | Outperform | $251 → $274 |
| 12 Aug 2026 | Citigroup | Maintains | Buy | $265 → $280 |
| 12 Aug 2026 | Evercore ISI Group | Maintains | Outperform | $265 → $270 |
| 12 Aug 2026 | Mizuho | Maintains | Outperform | $240 → $250 |
| 12 Aug 2026 | Morgan Stanley | Maintains | Overweight | $255 → $265 |
| 12 Aug 2026 | UBS | Maintains | Buy | $274 → $280 |
| 12 Aug 2026 | Wells Fargo | Maintains | Overweight | $245 → $277 |
| 24 July 2026 | Citigroup | Maintains | Buy | $245 → $265 |
| 24 July 2026 | Citigroup | Maintains | Buy | — |
| 23 July 2026 | Mizuho | Maintains | Outperform | — |
| 23 July 2026 | Mizuho | Maintains | Outperform | $235 → $240 |
| 20 July 2026 | UBS | Maintains | Buy | — |
| 20 July 2026 | UBS | Maintains | Buy | $260 → $274 |
| 9 July 2026 | TD Cowen | Maintains | Buy | $255 → $275 |
| 9 July 2026 | TD Cowen | Maintains | Buy | — |
| 2 July 2026 | B of A Securities | Maintains | Buy | $240 → $260 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CAH appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 16 Oct 2026, Cardinal Health, Inc. returned +67.3% against +16.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 22% of US stocks
Cheaper than 91% of US stocks
Cheaper than 98% of US stocks
Cheaper than 22% of US stocks
Higher than 41% of US stocks
Higher than 79% of US stocks
Higher than 6% of US stocks
Higher than 47% of US stocks
Higher than 49% of US stocks
Higher than 18% of US stocks
Higher than 70% of US stocks
Higher than 68% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Cardinal Health, Inc. has a market value of $58.7B and an enterprise value of $64.3B.
Revenue in the twelve months to 30 June 2026: $254.2B. The latest quarter grew 5.8% year on year.
Net income over the same four quarters: $1.7B, a 0.7% net margin.
Diluted earnings per share, trailing twelve months: $7.24.
Free cash flow in the twelve months to 30 June 2026: $4.5B.
Cardinal Health, Inc. spent $1.4B on share buybacks and $491.0M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 34.0×; forward P/E: 18.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.81%, paying out 28% of earnings.
Cardinal Health, Inc. employs 58,788 people — $4.3M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| CAHCardinal Health, Inc. | $58.7B | 96 |
| CORCencora, Inc. | $65.2B | 74 |
| MCKMcKesson Corp. | $116.9B | 90 |
| HSICHenry Schein, Inc. | $10.0B | 83 |
| NTRANatera, Inc.* | $55.9B | 82 |
| BDXBecton, Dickinson & Co.* | $53.4B | 94 |
| BSXBoston Scientific Corp.* | $65.4B | 55 |
* Nearest Healthcare names by size — few medical distribution companies of this scale trade in the US universe.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Cardinal Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Cardinal Health closed at $253.71 in the latest trading session, up 2.41% from the prior day.
Why it matters — CAH watchers may note the stock’s day-over-day gain in the latest session.
Zacks Investment Research identifies Cardinal Health, UnitedHealth Group and Corcept Therapeutics as low-beta healthcare stocks with expected earnings growth and defensive appeal amid rising inflation and energy costs.
Why it matters — The item frames CAH as a defensive healthcare stock with expected earnings growth in the current inflationary environment.
Zacks Investment Research’s headline describes Cardinal Health as a strong growth stock and points readers to Zacks Style Scores as a way to identify stocks for a portfolio.
Why it matters — The item frames CAH positively around growth and references Zacks’ stock-scoring approach, without providing supporting details in the excerpt.
Zacks Investment Research describes its focus on the Zacks Rank system, which uses earnings estimates and estimate revisions, while also monitoring value, growth, and momentum trends. The headline frames these factors around whether investors should consider Cardinal Health stock.
Why it matters — CAH watchers may note the article’s emphasis on earnings-estimate revisions and broader investment trends as its framework for evaluating the stock.
Zacks Investment Research compares Cardinal Health (CAH) and Alto Neuroscience (ANRO) with their sector, focusing on how they have performed so far this year.
Why it matters — The comparison gives CAH watchers context for the stock’s year-to-date performance relative to its sector.
The 17 Wall Street analysts covering Cardinal Health, Inc. have a median 12-month price target of $276, with estimates ranging from $235 to $292. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 17 analysts covering Cardinal Health, Inc., 14 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cardinal Health, Inc. 96 out of 100 across roughly 4,600 US stocks as at 15 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Oct 2026, Cardinal Health, Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).
No one can know that. What the data says: the median 12-month target from 17 analysts implies +8.6% from the last close, and Ticker Nerd's factor model ranks Cardinal Health, Inc. 96 out of 100 as at 15 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Cardinal Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CAH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $235 to $292 over the next 12 months.
Cardinal Health, Inc. returned +67.3% over the 12 months to 16 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Cardinal Health, Inc. is a healthcare services and products company that supports the flow of medicines, medical supplies, and related solutions across the healthcare system.
The most recent item we track (Zacks Investment Research, 15 Oct 2026): "Cardinal Health (CAH) Laps the Stock Market: Here's Why". Cardinal Health closed at $253.71 in the latest trading session, up 2.41% from the prior day.
Cardinal Health, Inc. is a healthcare services and products company that supports the flow of medicines, medical supplies, and related solutions across the healthcare system. Cardinal Health distributes pharmaceuticals and specialty products, manufactures and distributes medical and laboratory products, and provides performance and data solutions for healthcare facilities. Its operations serve hospitals, health systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients at home. The company also supplies home-health and direct-to-patient products and services, along with nuclear pharmacy and manufacturing capabilities that support specialized healthcare needs. With a broad role in healthcare logistics and product distribution, Cardinal Health, Inc. helps connect manufacturers, providers, and patients through integrated offerings that span the care continuum.
CEO Mr. Jason M. Hollar · 58,788 employees · United States · https://www.cardinalhealth.com
